基於人工智能的臨床試驗解決方案提供商的市場規模、份額和趨勢分析:按治療用途、臨床試驗階段、最終用途、地區、細分市場預測(2022-2030 年)
市場調查報告書
商品編碼
1097000

基於人工智能的臨床試驗解決方案提供商的市場規模、份額和趨勢分析:按治療用途、臨床試驗階段、最終用途、地區、細分市場預測(2022-2030 年)

AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region, And Segment Forecasts, 2022 - 2030

出版日期: | 出版商: Grand View Research | 英文 118 Pages | 商品交期: 2-10個工作天內

價格

基於人工智能的臨床試驗解決方案提供商市場的增長和趨勢

正觀研究最新報告顯示,到 2030 年,全球基於 AI 的臨床試驗解決方案提供商市場規模將達到 78 億美元,預測期內復合年增長率為 22.0%。預計會擴大。

人工智能是一種多功能工具,被用於提高藥物發現研究的運營效率並加速藥物發現過程。它也被高度採用以最小化藥物開發過程的成本。各種學術界和製藥公司都在積極採用基於人工智能的平台和技術。例如,2020 年 1 月,拜耳與一家總部位於英國的 AI 藥物發現公司合作,利用 AI 藥物發現平台開展了一項初步研究項目。此外,支持研發的公私合作努力以及人工智能在藥物研究領域提供的多樣化應用正在推動增長。

基於臨床試驗階段,由於藥物發現的增加和二期的大量活躍研究,二期將在 2021 年以 47.2% 的份額主導市場。此外,在整個臨床試驗階段,越來越多地採用基於人工智能的工具進行數據收集和對總體預期結果的即時分析,這也促進了細分市場的增長。此外,該細分市場的收入份額更高,因為它可以在此階段改進、確定和驗證基於 AI 的工具的措施。

2021 年,基於治療應用,腫瘤學在基於 AI 的臨床試驗解決方案提供商市場的收入份額最高。全球癌症發病率的增加以及腫瘤學領域藥物研究數量的增加正在促進人工智能技術的引入。此外,越來越多的參與者正在開發和採用先進的基於腫瘤學的人工智能工具進行藥物研究,這推動了細分市場的增長。

2021 年,基於最終用途,製藥公司在市場上的收入份額最高。診斷和生物標誌物的更好開發、新藥物靶點的識別以及領先製藥公司在藥物開發和藥物測試的整個過程中更多地採用基於人工智能的技術是細分市場增長的關鍵驅動力之一。此外,這些領先的製藥公司正在與人工智能供應商合作,在其研發和整體藥物發現過程中利用人工智能技術,從而推動增長。

北美在市場上占主導地位,2021 年的收入份額為 43.8%。這一優勢是由於該地區的初創企業數量不斷增加。例如,Bullfrog AI 是一家美國初創公司,開發 bfLEAP,這是一個獨特的人工智能平台,可以實現精準醫療。提高對基於人工智能的技術的認識和採用以增強藥物研究成果正在推動該地區的市場增長。此外,政府加大支持和大公司的戰略努力正在推動該地區對基於人工智能的臨床試驗解決方案的需求。

隨著 COVID-19 的爆發,基於 AI 的技術的採用率激增。越來越多地採用技術先進的解決方案進行藥物開發和分析採用的患者數據,推動了人工智能解決方案的採用激增。此外,在大流行期間,許多藥物開發過程被擱置。因此,市場上的許多主要參與者已將重點轉移到利用基於人工智能的解決方案上,從而推動分佈式藥物測試。此外,通過這些解決方案對大量患者數據進行有效分析有助於市場增長。

基於人工智能的臨床試驗解決方案提供商市場報告亮點

  • 由於人工智能在臨床試驗領域提供的各種應用以及製藥公司越來越多地採用這些平台,預計到 2030 年市場規模將達到 78 億美元。
  • 2021年二期臨床試驗領域市場規模壓倒性優勢,主要是由於同期活性藥物研究增加所致。
  • 由於癌症發病率的增加和腫瘤學領域的藥物研究增加,腫瘤學領域在 2021 年佔據了市場主導地位。
  • 由於主要製藥公司在藥物開發中越來越多地採用人工智能技術,製藥公司部門在市場上的利潤份額最高。
  • 在北美,該地區的臨床試驗數量正在增加,人工智能平台和工具的採用正在擴大,在藥物開發中基於人工智能的初創公司和公司數量正在增加,意識基於人工智能的工具和技術的數量正在增加,從多方面因素主導市場,2021年的收入份額達到43.8%。

目錄

第 1 章調查方法及範圍

  • 市場細分和範圍
  • 市場定義
  • 調查方法
    • 資訊採購
      • 購買的數據庫
      • GVR 內部數據庫
    • 初步調查
  • 調查範圍和先決條件
  • 數據源列表

第 2 章執行摘要

  • 市場展望
  • 細分市場展望

第 3 章全球基於人工智能的臨床試驗解決方案提供商的市場變量、趨勢和範圍

  • 滲透率和增長前景映射
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 全球基於人工智能的臨床試驗解決方案提供商市場分析工具
    • 行業分析-波特五力分析
      • 供應商議價能力
      • 買方的議價能力
      • 替代威脅
      • 來自新進入者的威脅
      • 競爭對手之間的敵對關係
    • PESTEL 分析
      • 政治局勢
      • 經濟和社會狀況
      • 技術情況
      • 法律狀況
      • 技術情況
    • 重大交易和戰略聯盟分析
  • COVID-19 對市場的影響

第 4 章基於AI的臨床試驗解決方案提供商市場:臨床試驗階段估計和趨勢分析

  • 定義和範圍
  • 全球基於 AI 的臨床試驗解決方案提供商市場:2021 年和 2030 年臨床試驗階段的市場份額分析
  • 第一階段
    • 2016-2030 年第一階段分析市場估計和預測(100 萬美元)
  • 第二階段
    • 2016-2030 年第二階段分析市場估計和預測(100 萬美元)
  • 第三階段
    • 2016-2030 年 III 期分析市場估計和預測(100 萬美元)

第 5 章基於 AI 的臨床試驗解決方案提供商市場:治療應用的估計和趨勢分析

  • 定義和範圍
  • 全球基於 AI 的臨床試驗解決方案提供商市場:2021 年和 2030 年治療應用市場份額分析
  • 腫瘤學
    • 2016-2030 年腫瘤學分析市場估計和預測(100 萬美元)
  • 心血管疾病
    • 2016-2030 年心血管疾病分析市場估計和預測(100 萬美元)
  • 神經系統疾病或神經系統疾病
    • 2016-2030 年神經系統疾病或狀況分析市場估計/預測(100 萬美元)
  • 代謝性疾病
    • 2016-2030 年代謝疾病分析市場估計/預測(100 萬美元)
  • 傳染病
    • 2016-2030 年傳染病分析市場估計/預測(100 萬美元)
  • 其他
    • 2016-2030 年其他分析市場估計/預測(100 萬美元)

第 6 章基於AI的臨床試驗解決方案提供商市場:最終用途估計和趨勢分析

  • 定義和範圍
  • 全球基於 AI 的臨床試驗解決方案提供商市場:2020 年和 2030 年最終用途市場份額分析
  • 製藥公司
    • 2016-2030 年製藥公司的分析市場估計和預測(100 萬美元)
  • 學術機構
    • 2016-2030 年學術機構分析市場估計/預測(100 萬美元)
  • 其他
    • 2016-2030 年其他分析市場估計/預測(100 萬美元)

第 7 章基於 AI 的臨床試驗解決方案提供商市場:區域估計/趨勢分析、臨床試驗階段、治療和最終用途

  • 全球基於人工智能的臨床試驗解決方案提供商市場:區域變異性分析
  • 北美
    • 2016-2030 年北美基於 AI 的臨床試驗解決方案提供商市場估計和預測臨床試驗階段、治療應用和最終用途(100 萬美元)
    • 美國
      • 2016-2030年美國基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 加拿大
      • 2016-2030年加拿大基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
  • 歐洲
    • 2016-2030年歐洲基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 英國
      • 2016-2030年英國基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 德國
      • 2016-2030年德國基於AI的臨床試驗解決方案提供商市場估計和預測(100萬美元)
    • 西班牙
      • 2016-2030年西班牙基於AI的臨床試驗解決方案提供商市場估計和預測(100萬美元)
    • 法國
      • 2016-2030年法國基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 義 大利
      • 2016-2030年意大利基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 俄羅斯
      • 俄羅斯基於AI的臨床試驗解決方案提供商,市場估計和預測,2016-2030年(100萬美元)
  • 亞太地區
    • 2016-2030 年亞太地區基於 AI 的臨床試驗解決方案提供商、市場估計/預測和臨床試驗階段、治療應用和最終用途預測(100 萬美元)
    • 中國
      • 2016-2030年中國基於AI的臨床試驗解決方案提供商市場預估與預測(百萬美元)
    • 日本
      • 2016-2030年日本基於AI的臨床試驗解決方案提供商市場預估與預測(100萬美元)
    • 印度
      • 2016-2030年印度基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
    • 韓國
      • 2016-2030 年韓國基於 AI 的臨床試驗解決方案提供商的市場估計和預測(100 萬美元)
    • 澳大利亞
      • 2016-2030年澳大利亞基於AI的臨床試驗解決方案提供商、臨床試驗階段、治療應用以及市場估計和預測,2016-2030年(100萬美元)
  • 拉丁美洲
    • 拉丁美洲基於 AI 的臨床試驗解決方案提供商,市場估計和預測,2016-2030 年(100 萬美元)
    • 巴西
      • 巴西基於 AI 的臨床試驗解決方案提供商,市場估計和預測,2016-2030 年(100 萬美元)
    • 墨西哥
      • 2016-2030年墨西哥基於AI的臨床試驗解決方案提供商市場預估與預測(100萬美元)
    • 阿根廷
      • 阿根廷基於AI的臨床試驗解決方案提供商,市場估計和預測,2016-2030年(100萬美元)
  • 中東/非洲
    • 中東/非洲基於人工智能的臨床試驗解決方案提供商,市場估計和預測,2016-2030 年(100 萬美元)
    • 南非
      • 2016-2030 年南非基於 AI 的臨床試驗解決方案提供商、市場估計和預測性臨床試驗階段、治療應用和最終用途(100 萬美元)
    • 沙特阿拉伯
      • 沙特阿拉伯基於人工智能的臨床試驗解決方案提供商、市場估計和預測臨床試驗階段、治療應用和最終用途 2016-2030(100 萬美元)
    • 阿拉伯聯合酋長國
      • 阿拉伯聯合酋長國基於人工智能的臨床試驗解決方案提供商、臨床試驗階段、治療和最終用途市場估計和預測,2016-2030 年(100 萬美元)

第 8 章公司簡介

  • Unlearn.AI, Inc.
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Saama Technologies
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Antidote Technologies, Inc.
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Exscientia
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Google Inc. (Verily)
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • IBM Watson
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • GNS Healthcare
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • BioSymetrics
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Euretos
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Koneksa Health
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Trials.Ai
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Ardigen
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Pharmaseal
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Halo Health Systems
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • DEEP LENS AI
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • CONSILX
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • AiCure, LLC
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • BioAge Labs, Inc.
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Symphony AI
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Median Technologies
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Intelligencia
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Mendel.ai
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Innoplexus
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Deep 6 AI
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Phesi
    • 公司簡介
    • 財務表現
    • 產品基準
    • 戰略舉措
Product Code: GVR-4-68039-456-6

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030 and is expected to expand at a CAGR of 22.0% over the forecast period, according to a new report by Grand View Research, Inc. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse application provided by AI in the field of drug studies is impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 47.2% in 2021 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2021, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2021, based on end-use, pharmaceutical companies accounted for the highest revenue share in the market. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for revenue share of 43.8% in 2021. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outburst of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

  • The market size is anticipated to be valued at USD 7.8 billion by 2030, owing to various applications provided by AI in the field of clinical trials and the growing adoption of such platforms by pharmaceutical companies
  • The phase-II trials segment dominated the market in 2021, owing to the increasing number of active drug studies in this phase
  • The oncology segment dominated the market in 2021, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
  • North America dominated the market and accounted for revenue share of 43.8% in 2021, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation and Scope
  • 1.2 Market Definition
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
      • 1.3.1.1 Purchased database
      • 1.3.1.2 GVR's internal database
    • 1.3.2 Primary Research
  • 1.4 Research Scope and Assumptions
  • 1.5 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook

Chapter 3 Global AI-based Clinical Trial Solution Providers Market Variables, Trends, & Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Market Restraint Analysis
  • 3.3 Global AI-based Clinical Trial Solution Providers Market Analysis Tools
    • 3.3.1 Industry Analysis - Porter's
      • 3.3.1.1 Bargaining power of the suppliers
      • 3.3.1.2 Bargaining power of the buyers
      • 3.3.1.3 Threats of substitution
      • 3.3.1.4 Threats from new entrants
      • 3.3.1.5 Competitive rivalry
    • 3.3.2 PESTEL Analysis
      • 3.3.2.1 Political landscape
      • 3.3.2.2 Economic and Social landscape
      • 3.3.2.3 Technology landscape
      • 3.3.2.4 Legal landscape
      • 3.3.2.5 Technology landscape
    • 3.3.3 Major Deals & Strategic Alliances Analysis
  • 3.4 COVID-19 Impact on the market

Chapter 4 AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

  • 4.1 Definitions & Scope
  • 4.2 Global AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Market Share Analysis, 2021 and 2030
  • 4.3 Phase-I
    • 4.3.1 Phase-I analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
    • 4.3.2 Phase-II
      • 4.3.2.1 Phase-II analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
    • 4.3.3 Phase-III
      • 4.3.3.1 Phase-III analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 5 AI-based Clinical Trial Solution Providers Market: Therapeutic Application Estimates & Trend Analysis

  • 5.1 Definitions & Scope
  • 5.2 Global AI-based Clinical Trial Solution Providers Market: Therapeutic Application Market Share Analysis, 2021 and 2030
  • 5.3 Oncology
    • 5.3.1 Oncology analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.4 Cardiovascular Diseases
    • 5.4.1 Cardiovascular Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.5 Neurological Diseases or Conditions
    • 5.5.1 Neurological Diseases or Conditions analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.6 Metabolic Diseases
    • 5.6.1 Metabolic Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.7 Infectious Diseases
    • 5.7.1 Infectious Diseases analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 5.8 Others
    • 5.8.1 Others analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 6 AI-based Clinical Trial Solution Providers Market: End-Use Estimates & Trend Analysis

  • 6.1 Definitions & Scope
  • 6.2 Global AI-based Clinical Trial Solution Providers Market: End-Use Market Share Analysis, 2020 and 2030
  • 6.3 Pharmaceutical Companies
    • 6.3.1 Pharmaceutical Companies analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 6.4 Academia
    • 6.4.1 Academia analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • 6.5 Others
    • 6.5.1 Others analysis Market Estimates and Forecasts, 2016 - 2030 (USD Million)

Chapter 7 AI-based Clinical Trial Solution Providers Market: Regional Estimates & Trend Analysis, By Clinical Trial Phase, Therapeutic Application & End-Use

  • 7.1 Global AI-based Clinical Trial Solution Providers Market: Regional Movement Analysis
  • 7.2 North America
    • 7.2.1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.2 U.K.
      • 7.3.2.1 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.3 Germany
      • 7.3.3.1 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.4 Spain
      • 7.3.4.1 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.5 France
      • 7.3.5.1 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.6 Italy
      • 7.3.6.1 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.3.7 Russia
      • 7.3.7.1 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.3 Japan
      • 7.4.3.1 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.4 India
      • 7.4.4.1 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.4.6 Australia
      • 7.4.6.1 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
  • 7.6 MEA
    • 7.6.1 MEA AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)
    • 7.6.4 UAE
      • 7.6.4.1 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2016 - 2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Unlearn.AI, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 Saama Technologies
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 Antidote Technologies, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.3 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Exscientia
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Google Inc. (Verily)
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
    • 8.5.4 Strategic Initiatives
  • 8.6 IBM Watson
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.3 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 GNS Healthcare
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 BioSymetrics
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.8.4 Strategic Initiatives
  • 8.9 Euretos
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 Koneksa Health
    • 8.10.1 Company Overview
    • 8.10.2 Financial Performance
    • 8.10.3 Product Benchmarking
    • 8.10.4 Strategic Initiatives
  • 8.11 Trials.Ai
    • 8.11.1 Company Overview
    • 8.11.2 Financial Performance
    • 8.11.3 Product Benchmarking
    • 8.11.4 Strategic Initiatives
  • 8.12 Ardigen
    • 8.12.1 Company Overview
    • 8.12.2 Financial Performance
    • 8.12.3 Product Benchmarking
    • 8.12.4 Strategic Initiatives
  • 8.13 Pharmaseal
    • 8.13.1 Company Overview
    • 8.13.2 Financial Performance
    • 8.13.3 Product Benchmarking
    • 8.13.4 Strategic Initiatives
  • 8.14 Halo Health Systems
    • 8.14.1 Company Overview
    • 8.14.2 Financial Performance
    • 8.14.3 Product Benchmarking
    • 8.14.4 Strategic Initiatives
  • 8.15 DEEP LENS AI
    • 8.15.1 Company Overview
    • 8.15.2 Financial Performance
    • 8.15.3 Product Benchmarking
    • 8.15.4 Strategic Initiatives
  • 8.16 CONSILX
    • 8.16.1 Company Overview
    • 8.16.2 Financial Performance
    • 8.16.3 Product Benchmarking
    • 8.16.4 Strategic Initiatives
  • 8.17 AiCure, LLC
    • 8.17.1 Company Overview
    • 8.17.2 Financial Performance
    • 8.17.3 Product Benchmarking
    • 8.17.4 Strategic Initiatives
  • 8.18 BioAge Labs, Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Financial Performance
    • 8.18.3 Product Benchmarking
    • 8.18.4 Strategic Initiatives
  • 8.19 Symphony AI
    • 8.19.1 Company Overview
    • 8.19.2 Financial Performance
    • 8.19.3 Product Benchmarking
    • 8.19.4 Strategic Initiatives
  • 8.20 Median Technologies
    • 8.20.1 Company Overview
    • 8.20.2 Financial Performance
    • 8.20.3 Product Benchmarking
    • 8.20.4 Strategic Initiatives
  • 8.21 Intelligencia
    • 8.21.1 Company Overview
    • 8.21.2 Financial Performance
    • 8.21.3 Product Benchmarking
    • 8.21.4 Strategic Initiatives
  • 8.22 Mendel.ai
    • 8.22.1 Company Overview
    • 8.22.2 Financial Performance
    • 8.22.3 Product Benchmarking
    • 8.22.4 Strategic Initiatives
  • 8.23 Innoplexus
    • 8.23.1 Company Overview
    • 8.23.2 Financial Performance
    • 8.23.3 Product Benchmarking
    • 8.23.4 Strategic Initiatives
  • 8.24 Deep 6 AI
    • 8.24.1 Company Overview
    • 8.24.2 Financial Performance
    • 8.24.3 Product Benchmarking
    • 8.24.4 Strategic Initiatives
  • 8.25 Phesi
    • 8.25.1 Company Overview
    • 8.25.2 Financial Performance
    • 8.25.3 Product Benchmarking
    • 8.25.4 Strategic Initiatives

List of Tables

  • Table 1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 2 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 3 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 4 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 5 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 6 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 7 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 8 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 9 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 10 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 11 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 12 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 13 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 14 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 15 U.K. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 16 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 17 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 18 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 19 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 20 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 21 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 22 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 23 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 24 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 25 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 26 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 27 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 28 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 29 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 30 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 31 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 32 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 33 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 34 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 35 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 36 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 37 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 38 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 39 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 40 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 41 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 42 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 43 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 44 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table46 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 47 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 48 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 49 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 50 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 51 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 52 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 53 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 54 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 55 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 56 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 57 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 58 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 59 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 60 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 61 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 62 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 63 Middle East & Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 64 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 65 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 66 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 67 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 68 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 69 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)
  • Table 70 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts, By Clinical Trial Phase, 2016 - 2030 (USD Million)
  • Table 71 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, By Therapeutic Application, 2016 - 2030 (USD Million)
  • Table 72 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, by End-Use, 2016 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 AI-based Clinical Trial Solution Providers market snapshot, 2021, (USD Million)
  • Fig. 6 AI-based Clinical Trial Solution Providers market trends & outlook
  • Fig. 7 Penetration & growth prospect mapping
  • Fig. 8 Market driver analysis (Current & future impact)
  • Fig. 9 Market restraint analysis (Current & future impact)
  • Fig. 10 AI-based Clinical Trial Solution Providers market, clinical trial phase outlook key takeaways (USD Million)
  • Fig. 11 AI-based Clinical Trial Solution Providers market: clinical trial phase movement analysis (USD Million), 2021 & 2030
  • Fig. 12 Phase-I Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 13 Phase-II Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 14 Phase-III Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 15 AI-based Clinical Trial Solution Providers market, therapeutic application outlook key takeaways (USD Million)
  • Fig. 16 AI-based Clinical Trial Solution Providers market: therapeutic application movement analysis (USD Million), 2020 & 2030
  • Fig. 17 Oncology Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 18 Cardiovascular diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 19 Neurological Diseases or Conditions Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 20 Metabolic Diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 22 Other Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 23 AI-based Clinical Trial Solution Providers market, end-use outlook key takeaways (USD Million)
  • Fig. 24 AI-based Clinical Trial Solution Providers market: end-use movement analysis (USD Million), 2020 & 2030
  • Fig. 25 Pharmaceutical companies Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 26 Academia Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 27 Others Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 28 AI-based Clinical Trial Solution Providers market, regional outlook key takeaways (USD Million)
  • Fig. 29 AI-based Clinical Trial Solution Providers market: regional movement analysis (USD Million), 2020 & 2030
  • Fig. 30 North America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 31 U.S. AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 32 Canada AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 33 Europe AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 34 U.K AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 35 Germany AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 36 Spain AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 37 France AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 38 Italy AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 39 Russia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 40 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 41 China AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 42 Japan AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 43 India AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 44 South Korea AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 45 Australia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 46 Latin America AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 47 Brazil AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 48 Mexico AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 49 Argentina AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 50 MEA AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 51 South Africa AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)
  • Fig. 53 UAE AI-based Clinical Trial Solution Providers Market Estimates and Forecasts, 2016 - 2030 (USD Million)